

Quick Search All fields Author
 search tips Journal/book title Volume Issue Page Clear Go [Advanced Search](#)

Font Size:

Purchase PDF (677 K) [Export Citation](#)

Abstract [Article](#) [Figures/Tables](#) [References](#)

Molecular Genetics and Metabolism
 Volume 100, Issue 4, August 2010, Pages 309-315

doi:10.1016/j.ymgme.2010.05.001 | [How to Cite or Link Using DOI](#)
 Copyright © 2010 Elsevier Inc. All rights reserved.

[Permissions & Reprints](#)

Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease

Karen M. Ashe^{1, a}, Kristin M. Taylor^{1, a},
 Qiuming Chu^a, Elizabeth Meyers^a, Allen
 Ellis^a, Varvara Jingozyan^a, Katherine
 Klinger^a, Patrick F. Finn^a, Christopher G.F.
 Cooper^a, Wei-Lien Chuang^a, John Marshall^a,
 John M. McPherson^a, Robert J. Mattaliano^a,
 Seng H. Cheng^a, Ronald K. Scheule^a and
 Rodney J. Moreland[✉]

Purchase the full-text article

- ▶ PDF and HTML
- ▶ All references
- ▶ All images
- ▶ All tables

^a Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701-9322, USA
 Received 12 March 2010; revised 30 April 2010; accepted 1 May 2010. Available online
 5 May 2010.

Abstract

Pompe disease, also known as glycogen storage disease (GSD) type II, is caused by deficiency of lysosomal acid α -glucosidase (GAA). The resulting glycogen accumulation causes a spectrum of disease severity ranging from a rapidly progressive course that is typically fatal by 1–2 years of age to a more slowly progressive course that causes significant morbidity and early mortality in children and adults. Recombinant human GAA (rhGAA) improves clinical outcomes with variable results. Adjunct therapy that increases the effectiveness of rhGAA may benefit some Pompe patients. Co-administration of the mTORC1 inhibitor rapamycin with rhGAA in a GAA knockout mouse reduced muscle glycogen content more than rhGAA or rapamycin alone. These results suggest mTORC1 inhibition may benefit GSDs that involve glycogen accumulation in muscle.

Keywords: mTOR; Pompe disease; Glycogen storage disease; Glycogen synthase; Rapamycin; Enzyme replacement therapy

Article Outline

Related Articles

- [Murine muscle cell models for Pompe disease and their u...](#)
Molecular Genetics and Metabolism
- [Pompe disease \(glycogen storage disease type II\) in Arg...](#)
Neuromuscular Disorders
- [Biochemical and pharmacological characterization of dif...](#)
Molecular Genetics and Metabolism
- [Pompe disease: Current state of treatment modalities an...](#)
Molecular Genetics and Metabolism
- [Cross-reactive immunologic material status affects trea...](#)
Molecular Genetics and Metabolism

[View More Related Articles](#)

[Introduction](#)

[Results](#)

[Discussion](#)

[Materials and methods](#)

[Reagents and antibodies](#)

[Animal studies](#)

[Preparation of tissue homogenates](#)

[Western blot analysis of tissue homogenates](#)

[Measurement of tissue glycogen](#)

[Measurement of anti-rhGAA and anti- \$\alpha\$ -gal antibody titer](#)

[Statistical analysis](#)

[Acknowledgements](#)

[References](#)

Corresponding author. Fax: +1 508 271 4776.

Molecular Genetics and Metabolism

Volume 100, Issue 4, August 2010, Pages 309-315

Sponsored Links

[Pompe Movie](#)

Development of a
medicine for Pompe.

genzyme.com/pompemovie

[mTOR inhibitors for R & D](#)

AZD8055, OSI-027 and Pp242

In stock, Toll-free 1-877-343-657

www.chemietek.com

[Depression Clinical](#)

Symptoms, causes, treatments of
Depression Clinical.

myOptumHealth.com

[Home](#) [Browse](#) [Search](#) [My Settings](#) [Alerts](#) [Help](#)



[About ScienceDirect](#) | [Contact Us](#) | [Information for Advertisers](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2010 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.